MPTP-based Inducible Models

Target dopaminergic cell loss in an inducible MPTP-based Parkinson’s Disease model

Home » Neurology Research Models and Services  » Parkinson’s models and services » Parkinson’s models – MPTP-based Inducible Models
Parkinson’s disease (PD) is a neurodegenerative disorder that affects the motor systems in early stages, leading to symptoms such as trembling, slowing of movement, and muscle stiffness. The distinct disease mechanism can be modelled in different mouse models of PD.  

Degeneration of dopaminergic cells in the substantia nigra (SN) is the primary cause of the motor symptoms in PD. Administration of the MPTP, a pro-drug for the neurotoxin MPP+, selectively induces dopaminergic cell toxicity in the SN, representing one of the most widely used mouse PD models.

InnoSer offers unique services using several inducible in vivo PD models, including MPTP-based PD models. In-house validation experiments show that MPTP-induced PD models show loss of dopaminergic SN neurons, motor impairment, and activation of the NLRP3 inflammasome. As different MPTP dosing regimens lead to distinct neurodegenerative phenotypes; the choice of the model depends on your experimental compound’s hypothesized mechanism of action and research goals. 

 Take advantage of InnoSer’s expertise, flexibility and collaborative approach for your research. Our in-house neurology experts have long standing experience with modelling PD in vivo and are help guide your decision on choosing the best model fit for your current research goals. 

MPTP-based inducible model key features:

  • Acute and (sub)chronic varying dosing regimens possible, leading to distinct phenotypes.
  • Dopaminergic neuronal loss documented in the SN.
  • Motor impairments.
  • Neuroinflammation (e.g., NLRP3 inflammasome activation).
  • Suitable for testing anti-neuroinflammatory and neuroprotective compounds.

Find the right model for you.

Compare our model capabilities and discover which of our neurology platforms suits your research needs

Belgian based preclinical neurology CRO mouse models

Key readouts

Test the efficacy of your treatments in the following battery of behavioural tests:

Test the efficacy of your treatments with the following biological readouts:

  • (Digital) histopathology 
  • Immunohistochemistry (dopamine neurons, neuroinflammation) 
  • Immunofluorescence and FISH

Related Parkinson’s Disease model options


InnoSer has extensive experience with the administration of neurotoxic compounds such as 6-OHDA to induce PD phenotypes in vivo.

Transgenic Alpha-Synuclein Models

InnoSer offers fee-for-service transgenic α-syn mouse models.

Seeding Alpha-Synuclein Models

InnoSer has extensive experience with α-syn seeding using both PD patient-derived brain extracts and recombinant seeds.

AAALAC Accreditation

InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.


Animal Welfare

The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.

Need more information?

If you have any questions about how we can help accelerate your research,

then let us know